Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Immunopurified clotting factor concentrates

G Mariani¹, G D Di Nucci, P Arcieri

¹Department of Human Biopathology, University of Rome La Sapienza, Italy.

Nouvelle Revue Francaise D'Hematologie

|January 1, 1994

Summary

High-purity factor concentrates for hemophilia treatment are safe and effective. These monoclonally purified products demonstrate excellent viral safety, do not increase inhibitor formation, and have no adverse immune effects in HIV-positive patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Contact activation and factor VII after the use of an activated prothrombin complex concentrate (FEIBA) in hemophiliacs with inhibitors.

Thrombosis research·2010

Same author

Comparative performance of two inhaler systems to assess distribution of convective ventilation by 99mTc-labeled aerosol scintigraphy in patients with airway obstruction.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2009

Same author

Factor VII deficiency: defining the clinical picture and optimizing therapeutic options.

Haemophilia : the official journal of the World Federation of Hemophilia·2009

Same author

Ramus marginalis mandibulae nervus facialis palsy in hemifacial microsomia.

European journal of paediatric dentistry·2008

Same author

Polychlorinated biphenyls (PCBs) in the atmosphere of sub-alpine northern Italy.

Environmental pollution (Barking, Essex : 1987)·2008

Same author

Anaplastic thyroid cancer: prevalence, diagnosis and treatment.

Minerva endocrinologica·2008

Area of Science:

Hematology
Biochemistry
Immunology

Background:

Monoclonally purified factor concentrates for hemophilia A (FVIII) and B (FIX) have been used since the late 1980s.
These concentrates are characterized by high factor purity and minimal contaminants, enhancing safety.
Purification processes include viral inactivation, significantly reducing viral load.

Purpose of the Study:

To evaluate the safety and efficacy of monoclonally purified factor concentrates in hemophilia treatment.
To assess viral safety, inhibitor development, immune system effects, and thrombotic complications associated with these concentrates.

Main Methods:

Analysis of prospective studies in previously untreated patients.
Review of extensive production and usage data.
Evaluation of long-term administration effects in HIV-positive hemophiliacs.
Assessment of thrombotic events in high-risk surgical patients receiving FIX concentrate.

Main Results:

Demonstrated viral safety through prospective studies and extensive usage without reported adverse effects.
Monoclonal concentrates do not increase the frequency of inhibitor development to FVIII or FIX.
Long-term administration showed no adverse immune system effects in HIV-positive hemophiliacs.
Highly purified FIX concentrate showed no thrombotic complications, even in high-risk patients.

Conclusions:

Monoclonally purified factor concentrates are safe and effective for hemophilia treatment.
These concentrates offer significant improvements in viral safety and do not increase inhibitor risk.
FIX concentrate is particularly safe regarding thrombotic complications, offering an advantage over older treatments.

Related Experiment Videos